Skip to content
Screener

Perspective Therapeutics CATX Operating Income

Operating Income at other companies

CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$23.78M-1,749%
Immunome logo
ImmunomeIMNM
-$78.14M-68.1%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$100.22M+13.9%
uniQure logo
uniQureQURE
-$52.2M-19.0%
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
-$5.23M-62.2%
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
$739M+13.0%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Net income-$26.8M-24.7%
EPS (diluted)-$0.22+24.1%

Balance sheet

See full
Cash & equivalents$48.5M+68.1%
Total debt$3.9M+11.1%
Total equity$323.9M+21.9%
Total assets$392.0M+26.2%

Cash flow

See full
Operating cash flow-$20.7M-3.5%
CapEx$14.2M+1,284%
Free cash flow-$34.8M-66.1%

Valuation

See full
Market cap$342.14M+25.3%
Enterprise value$297.56M+20.1%

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp

Returns & leverage

See full
Return on equity-39.5%+14.0pp
Debt / equity0×0.0×
Current ratio6.6×-8.5×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Perspective Therapeutics’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:34 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-342512
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development21,54416,62042,91630,952
General and administrative7,7957,70914,78015,551
Total operating expenses29,33924,32957,69646,503
Operating loss(29,258)(24,039)(57,539)(45,871)
Non-operating income (expense):
Interest income2,3472,1594,5444,543
Interest and other expense(71)(119)(176)(247)
Other income from a related party (Note 3)---1,400

ITEM 1 - FINANCIAL STATEMENTS

FAQ

What is Perspective Therapeutics's operating income?
Perspective Therapeutics (CATX) reported operating income of -$29.26M in Q2 2026.
How has Perspective Therapeutics's operating income changed year-over-year?
Perspective Therapeutics's operating income decreased by 21.7% year-over-year, from -$24.04M to -$29.26M.
What is the long-term trend for Perspective Therapeutics's operating income?
Over 3 years (2022 to 2025), Perspective Therapeutics's operating income has grown at a 145.3% compound annual growth rate (CAGR), from -$7.69M to -$113.56M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Perspective Therapeutics's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude